• Total Revenue: $14.7 billion for 2024, up 2% year over year.
• Adjusted EBITDA: Approximately $4.7 billion for 2024.
• Adjusted EPS: $2.65 per share for 2024.
• Free Cash Flow: Approximately $2.6 billion for 2024, excluding divestiture-related taxes and transaction costs.
• New Product Revenues: $582 million for 2024.
• Debt Reduction: Approximately $3.7 billion retired in 2024.
• Capital Returned to Shareholders: Approximately $825 million through dividends and share repurchases in 2024.
• 2025 Revenue Impact from Indore Facility: Estimated negative impact of $500 million.
• 2025 Adjusted EBITDA Impact from Indore Facility: Estimated negative impact of $385 million.
• Gross Margin: 58% for 2024.
• Debt Leverage: Achieved gross leverage target of approximately 2.9 times by end of 2024.
• Share Repurchase Authorization: $1.5 billion available.

• Warning! GuruFocus has detected 3 Warning Signs with VTRS.

Release Date: February 27, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Viatris Inc (NASDAQ:VTRS) achieved a full year revenue growth of 2% on a divestiture adjusted operational basis, aligning with their guidance.
• The company successfully returned approximately $825 million to shareholders through dividends and share repurchases.
• Viatris Inc (NASDAQ:VTRS) retired approximately $3.7 billion of debt, achieving their long-term gross leverage target.
• The company expanded its innovative portfolio with three new products: Selatogrel, Cenerimod, and Sotagliflozin.
• Viatris Inc (NASDAQ:VTRS) reported strong free cash flow of approximately $2.6 billion, excluding divestiture-related taxes and transaction costs.

Negative Points

• The FDA issued a warning letter and import alert for Viatris Inc (NASDAQ:VTRS)'s facility in Indore, India, impacting 11 actively distributed products in the US.
• The company anticipates a negative impact on 2025 total revenues of approximately $500 million due to the Indore facility issues.
• The Indore situation is expected to negatively impact 2025 adjusted EBITDA by approximately $385 million.
• Viatris Inc (NASDAQ:VTRS) expects total revenues to decline approximately 1% in 2025, primarily due to the Indore facility issues.
• The company faces potential competition and price erosion in North America, affecting certain generics like Xulane and others.

Q & A Highlights

Q: Can you discuss your confidence that the quality control issues at the Indore facility are isolated and not indicative of broader problems across other facilities? A: Scott Smith, CEO: We had three facilities inspected in 2024. Indore received a warning letter and import alert, but our Carroll Park facility in Australia was closed out with no issues, and the classification for our Nasha, India facility is pending. All other facilities are in compliance with health authorities. Indore is just one of 26 facilities in our network.

Q: Regarding Cenerimod and Selatogrel, can we expect data from these programs in 2026 or 2027? A: Philippe Martin, Chief R&D Officer: We expect data for both programs in late 2026. Enrollment is progressing well, so it could be earlier if trends continue.

Q: Given the current stock price drop, why not be more aggressive with share buybacks beyond the guided range? A: Scott Smith, CEO: We plan to return $1 billion to $1.2 billion to shareholders through dividends and buybacks. We will evaluate the share price and consider increasing buybacks beyond the $500 million to $650 million range if the stock remains under pressure.

Q: Can you elaborate on the scope and timing of the enterprise review mentioned in the call? A: Scott Smith, CEO: The review is timely given past mergers and divestitures. It will assess our cost structure and resource allocation to ensure we are fit for future goals. Discussions have started, and we expect cost benefits to be realized in 2026.

Q: Why does the Indore facility issue impact revenues outside the US, and what are your generic pipeline assumptions for 2025? A: Scott Smith, CEO: Remediation efforts can cause supply issues, affecting product availability in Europe. We have 26 global facilities and seek alternate sources during remediation. Doretta Mistras, CFO: We are confident in achieving $450 million to $550 million in new product revenues, with 20% from already approved products and several complex products in the pipeline.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.